CapsoVision, Inc. Common Stock Net Assets
CapsoVision, Inc. Common Stock net assets. Based on the latest financial reports, CapsoVision, Inc. Common Stock (CV) has net assets worth $13.17 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($18.57 Million) and total liabilities ($5.40 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore CapsoVision, Inc. Common Stock annual equity growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $13.17 Million |
| % of Total Assets | 70.9% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Net Assets of CapsoVision, Inc. Common Stock (2023–2025)
Net assets of CapsoVision, Inc. Common Stock from 2023 to 2025. This chart illustrates how CapsoVision, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. See how leveraged is CapsoVision, Inc. Common Stock's balance sheet to measure how much of total assets are equity-financed.
Annual Net Assets for CapsoVision, Inc. Common Stock (2023–2025)
The table below shows the annual net assets of CapsoVision, Inc. Common Stock from 2023 to 2025. For live market cap and overall valuation, see CV company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $13.26 Million | +110.24% |
| 2024-12-31 | $-129.51 Million | -17.90% |
| 2023-12-31 | $-109.84 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to CapsoVision, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4521300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
CapsoVision, Inc. Common Stock Net Assets Breakdown (December 2025)
CapsoVision, Inc. Common Stock net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $47.00K | 0.35% |
| Other Components | $168.88 Million | 1273.59% |
| Total Equity | $13.26 Million | 100.00% |
CapsoVision, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of CapsoVision, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Lanpec Technologies Ltd
SHG:601798
|
$352.26 Million |
|
Bank Bukopin Tbk
JK:BBKP
|
$352.26 Million |
|
Jing Jin Electric Technologies Co Ltd
SHG:688280
|
$352.38 Million |
|
Dongguan Chitwing Technology Co Ltd
SHE:002855
|
$352.66 Million |
|
medmix AG
SW:MEDX
|
$352.23 Million |
|
Third Point Investors Limited
LSE:TPOU
|
$352.20 Million |
|
Atria Oyj A
HE:ATRAV
|
$351.97 Million |
|
Annil Co Ltd
SHE:002875
|
$351.92 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CapsoVision, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -129,510,000 to 13,260,000, a change of 142,770,000.
- Net loss of 25,315,000 reduced equity.
- New share issuances of 26,557,000 increased equity.
- Other factors increased equity by 141,528,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-25.32 Million | -190.91% |
| Share Issuances | $26.56 Million | +200.28% |
| Other Changes | $141.53 Million | +1067.33% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares CapsoVision, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 23.68x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2023-12-31 | $-2.84 | $6.70 | x |
| 2024-12-31 | $-2.79 | $6.70 | x |
| 2025-12-31 | $0.28 | $6.70 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CapsoVision, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -190.91%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -186.77%
- • Asset Turnover: 0.75x
- • Equity Multiplier: 1.37x
- Recent ROE (-190.91%) is below the historical average (-63.64%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2023 | 0.00% | -115.91% | 0.45x | 0.00x | $-320.70K |
| 2024 | 0.00% | -169.26% | 0.70x | 0.00x | $-6.95 Million |
| 2025 | -190.91% | -186.77% | 0.75x | 1.37x | $-26.64 Million |
Industry Comparison
This section compares CapsoVision, Inc. Common Stock's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $296,528,539
- Average return on equity (ROE) among peers: -35.30%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CapsoVision, Inc. Common Stock (CV) | $13.17 Million | 0.00% | 0.41x | $352.25 Million |
| Abbott Laboratories (ABT) | $2.83 Billion | 34.08% | 0.96x | $190.23 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-95.88 Million | 0.00% | 0.00x | $2.34 Million |
| Aethlon Medical Inc (AEMD) | $-3.66 Million | 0.00% | 0.00x | $1.11 Million |
| Acutus Medical Inc (AFIB) | $-11.59 Million | 0.00% | 0.00x | $903.35K |
| Adapthealth Corp (AHCO) | $15.14 Million | -140.98% | 14.05x | $850.46 Million |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $9.37 Million | 23.33% | 0.30x | $2.43 Million |
| Allurion Technologies, Inc. (ALUR) | $-77.98 Million | 0.00% | 0.00x | $21.01K |
| Autonomix Medical, Inc. Common Stock (AMIX) | $5.89 Million | -283.55% | 0.29x | $1.61 Million |
| Artivion Inc (AORT) | $276.20 Million | -4.84% | 1.86x | $1.03 Billion |
| Apyx Medical Inc (APYX) | $14.18 Million | 18.92% | 0.18x | $109.52 Million |
About CapsoVision, Inc. Common Stock
CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement … Read more